Literature DB >> 7816067

Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.

S C Manolagas1, R L Jilka.   

Abstract

Both osteoblasts and osteoclasts are derived from progenitors that reside in the bone marrow; osteoblasts belong to the mesenchymal lineage of the marrow stroma, and osteoclasts to the hematopoietic lineage. The development of osteoclasts from their progenitors is dependent on stromal-osteoblastic cells, which are a major source of cytokines that are critical in osteoclastogenesis, such as interleukin-6 and interleukin-11. The production of interleukin-6 by stromal osteoblastic cells, as well as the responsiveness of bone marrow cells to cytokines such as interleukin-6 and interleukin-11, is regulated by sex steroids. When gonadal function is lost, the formation of osteoclasts as well as osteoblasts increases in the marrow, both changes apparently mediated by an increase in the production of interleukin-6 and perhaps by an increase in the responsiveness of bone marrow progenitor cells not only to interleukin-6 but also to other cytokines with osteoclastogenic and osteoblastogenic properties. The cellular activity of the bone marrow is also altered by the process of aging. Specifically, senescence may decrease the ability of the marrow to form osteoblast precursors. The association between the dysregulation of osteoclast or osteoblast development in the marrow and the disruption of the balance between bone resorption and bone formation, resulting in the loss of bone, leads to the following notion. Like homeostasis of other regenerating tissues, homeostasis of bone depends on the orderly replenishment of its cellular constituents. Excessive osteoclastogenesis and inadequate osteoblastogenesis are responsible for the mismatch between the formation and resorption of bone in postmenopausal and age-related osteopenia. The recognition that changes in the numbers of bone cells, rather than changes in the activity of individual cells, form the pathogenetic basis of osteoporosis is a major advance in understanding the mechanism of this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7816067     DOI: 10.1056/NEJM199502023320506

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  329 in total

1.  Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.

Authors:  R L Jilka; R S Weinstein; T Bellido; P Roberson; A M Parfitt; S C Manolagas
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

2.  M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss.

Authors:  S Cenci; M N Weitzmann; M A Gentile; M C Aisa; R Pacifici
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

3.  Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology.

Authors:  E M Scott; I Gaywood; B B Scott
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

4.  IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.

Authors:  A C Bendixen; N K Shevde; K M Dienger; T M Willson; C D Funk; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

5.  Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.

Authors:  S Cenci; M N Weitzmann; C Roggia; N Namba; D Novack; J Woodring; R Pacifici
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

6.  Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.

Authors:  C Schulte; H Goebell; H D Röher; K M Schulte
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 7.  Genetics of osteoporosis.

Authors:  S H Ralston
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 8.  Treatment of postmenopausal osteoporosis: an evidence-based approach.

Authors:  C J Rosen
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

9.  Differentially expressed genes in PPARγ-deficient MSCs.

Authors:  Yun Su; Xiaona Shen; Jie Chen; Carlos M Isales; Jing Zhao; Xing-Ming Shi
Journal:  Mol Cell Endocrinol       Date:  2017-07-31       Impact factor: 4.102

10.  Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency.

Authors:  M Neale Weitzmann; Cristiana Roggia; Gianluca Toraldo; Louise Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.